Peptides / Sexual health and hormones

Synthetic analog · 10 amino acids · 1,632.3 Da

Degarelix

ApprovedNot banned in sport

Degarelix (Firmagon) is a GnRH antagonist approved in the US and EU for advanced prostate cancer. Studies in people tested it on testosterone and other sex hormones, tumor growth, sexual function and bladder control, and tracked side effects. PepBank shows 252 results on degarelix from 43 studies in people, and 77 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Firmagon

10 amino acids, from first to lastXXXSXXLXPA

Evidence level: Large trials in people252 of 329 results come from studies in people, including randomized trials.

Results in people

252

77% of 329 results

Results in animals

18% of 329 results

Results in lab cells

5% of 329 results

From computer models

0% of 329 results

Overview

Degarelix at a glance

What it is	Synthetic analog, 10 amino acids
Approval	Approved in the US and EU (Firmagon)
In sport	Not listed as banned by WADA
Studies	60 studies with results. All of them gave degarelix, with 329 results. 252 in people59 in animals18 in lab cells
Best study in people	Randomized controlled trial with 379 people (2025)
Clinical trials	148 registered: 39 active or planned, 55 with posted results
Community use	Maintenance treatment of advanced prostate cancer after the labeled loading dose

The science

What is degarelix?

Degarelix is a synthetic ten-residue GnRH receptor antagonist.

Amino acids in one chain

The history of degarelix

2002
The oldest paper on degarelix in PepBank is from 2002.
2006January
A registered trial of degarelix started (NCT00268892).

Degarelix structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 10 amino acidsFrom the first amino acid to the last

X1XXSX5XLXPA10

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Degarelix is a synthetic analog of 10 amino acids, with no ring, 7 changed amino acids.

Formula

C₈₂H₁₀₃ClN₁₈O₁₆

Molecular weight

1,632.3 g/mol

CAS number

214766-78-6

Target

Gonadotropin-releasing hormone receptor (gene GNRHR): antagonistEvidence: Official prescribing information, mechanism of action

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 16136245, ChEMBL CHEMBL415606, UNII SX0XJI3A11, DrugBank DB06699

Full sequence, SMILES and InChIKey

InChIKey
MEUCPCLKGZSHTA-XYAYPHGZSA-N

SMILES
C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C

See charge, composition and 3D structure on the Scientific page

The evidence

What degarelix studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people252 of 329 results come from studies in people, including randomized trials.

Sex hormones and fertility

84 results · 62 in people · 22 animal

In Chinese men with prostate cancer, degarelix was non-inferior to goserelin for maintaining castrate testosterone. Asian journal of urology, 2020

Top results

In Chinese men with prostate cancer, degarelix was non-inferior to goserelin for maintaining castrate testosterone. (Asian journal of urology, 2020)
In oocyte donors, mid-luteal degarelix lowered FSH compared with placebo before stimulation. (Reproductive biomedicine online, 2012)
In Japanese prostate cancer patients, degarelix was non-inferior to goserelin for castration rate. (Cancer science, 2018)

Cancer

69 results · 60 in people · 8 animal · 1 lab

Degarelix did not significantly improve PSA response compared with an LHRH agonist. European urology oncology, 2025

Top results

Degarelix did not significantly improve PSA response compared with an LHRH agonist. (European urology oncology, 2025)
In men with prostate cancer, prostate volume reductions were similar with degarelix and goserelin plus bicalutamide. (Clinical oncology, 2013)
In men with recurrent prostate cancer, time off treatment did not differ after 10 versus 4 months of degarelix. (The Journal of urology, 2018)

Sexual and women's health

20 results · 20 in people

In men with pedophilic disorder, degarelix reduced the composite risk score more than placebo at 2 weeks. JAMA psychiatry, 2020

Top results

In men with pedophilic disorder, degarelix reduced the composite risk score more than placebo at 2 weeks. (JAMA psychiatry, 2020)
In men with pedophilic disorder, degarelix reduced sexual desire scores more than placebo at two weeks. (The world journal of biological psychiatry, 2022)
In localized prostate cancer, erectile function scores did not differ significantly between degarelix and GnRH agonists. (Andrology, 2022)

Kidneys and bladder

14 results · 14 in people

In prostate cancer patients, degarelix was non-inferior to goserelin plus bicalutamide for urinary symptom reduction. Urologia internationalis, 2013

Top results

In prostate cancer patients, degarelix was non-inferior to goserelin plus bicalutamide for urinary symptom reduction. (Urologia internationalis, 2013)
In localized prostate cancer, prostate volume reduction was comparable after degarelix and GnRH agonists. (Andrology, 2022)
In prostate cancer patients, degarelix reduced urinary symptom scores more than goserelin plus bicalutamide. (Lower urinary tract symptoms, 2017)

Heart and blood vessels

16 results · 11 in people · 5 animal

Among patients with existing cardiovascular disease, fewer cardiovascular events occurred with degarelix than an LHRH agonist. European urology oncology, 2025

Top results

Among patients with existing cardiovascular disease, fewer cardiovascular events occurred with degarelix than an LHRH agonist. (European urology oncology, 2025)
In healthy men, upper confidence boundaries for QTcF changes with degarelix versus placebo did not exceed 10 ms. (Clinical drug investigation, 2017)
In hormone-naive prostate cancer, secondary metabolic changes did not differ between degarelix and leuprolide plus bicalutamide. (World journal of urology, 2020)

Daily life and fitness

6 results · 6 in people

In men with pedophilic disorder, EuroQol index scores did not differ between degarelix and placebo at 2 weeks. JAMA psychiatry, 2020

Top results

In men with pedophilic disorder, EuroQol index scores did not differ between degarelix and placebo at 2 weeks. (JAMA psychiatry, 2020)
In men with recurrent prostate cancer, quality of life suffered less after 4 than 10 months of degarelix. (The Journal of urology, 2018)
In prostate cancer patients, more patients improved their quality of life with degarelix than goserelin plus bicalutamide. (Urologia internationalis, 2013)

Degarelix has 289 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 60 degarelix studies by area Open the Scientific page

Key degarelix studies

Studies in people come first, then studies in animals and in the lab.

People
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial
Zilli et al. 2025 · European urology oncology · 379 people · cited by 2
5 results
People
Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
Sun et al. 2020 · Asian journal of urology · 283 people · cited by 22
5 results
People
Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide
Mason et al. 2013 · Clinical oncology (Royal College of Radiologists (Great Britain)) · 244 people · cited by 56
3 results
People
Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
Ozono et al. 2018 · Cancer science · 234 people · cited by 19
6 results
People
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide
Axcrona et al. 2012 · BJU international · 175 people · cited by 81
4 results

All 60 Degarelix studies

Degarelix clinical trials

ClinicalTrials.gov lists 148 trials of degarelix. 39 are active or planned, and 55 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Phase 3completed1,538 people

A Trial of Degarelix in Patients With Prostate Cancer

Phase 3completed859 people

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Phase 3completed620 people

All 63 Degarelix trials

Status and safety

Is degarelix approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Firmagon). The FDA label for Firmagon says: “Treatment of patients with advanced prostate cancer” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Degarelix side effects and safety

PepBank has 73 safety results from studies of degarelix. 73 of them come from studies in people.

Safety results from studies (73)

In hospitalized men with COVID-19, inpatient mortality did not differ between degarelix and placebo. (JAMA network open, 2022)
In prostate cancer patients, urinary infection-related adverse events did not differ between degarelix and goserelin plus bicalutamide. (Lower urinary tract symptoms, 2017)
Adverse events occurred in 88% with degarelix and 89% with an LHRH agonist. (European urology oncology, 2025)
In Chinese men with prostate cancer, adverse events were similar with degarelix and goserelin except for injection site reactions. (Asian journal of urology, 2020)
Hot flush occurred in 61% of prostate cancer patients receiving degarelix versus 57% receiving relugolix. (European urology, 2020)
In men with recurrent prostate cancer, quality of life suffered less after 4 than 10 months of degarelix. (The Journal of urology, 2018)
In healthy men, upper confidence boundaries for QTcF changes with degarelix versus placebo did not exceed 10 ms. (Clinical drug investigation, 2017)
Injection site reactions occurred in 88% with degarelix versus 4% with placebo in men with pedophilic disorder. (JAMA psychiatry, 2020)
In prostate cancer patients, injection site reactions were more frequent with degarelix than goserelin plus bicalutamide. (Urologia internationalis, 2013)
In prostate cancer patients, injection-site reactions were higher with degarelix than leuprolide, 40% versus <1%. (BJU international, 2008)
In prostate cancer patients, degarelix and goserelin plus bicalutamide were both reported as safe and well tolerated. (BJU international, 2012)
In prostate cancer patients, mean QTcF change did not differ significantly between degarelix and leuprolide. (The Journal of urology, 2010)
In prostate cancer patients, hot flushes began sooner with degarelix than leuprolide. (Prostate cancer and prostatic diseases, 2011)
In prostate cancer patients, adverse event frequency was similar between continued and switched degarelix groups. (The Journal of urology, 2011)
In prostate cancer patients in the degarelix extension, adverse event frequency was similar between both groups. (Urology, 2014)
In Japanese prostate cancer patients receiving degarelix, 6.6% withdrew due to adverse events. (Japanese journal of clinical oncology, 2012)
In prostate cancer patients receiving degarelix, no evidence of testosterone surge was detected. (European urology, 2008)
In Japanese prostate cancer patients receiving degarelix, injection-site reaction was the most frequent adverse event. (Japanese journal of clinical oncology, 2017)
In prostate cancer patients, adverse events were comparable after switching to degarelix from leuprolide, except injection site reactions. (International journal of clinical practice, 2011)
In prostate cancer patients receiving degarelix, no evidence of testosterone surge was detected. (The Journal of urology, 2008)
In Japanese prostate cancer patients, injection site reactions were the most common adverse events with degarelix. (Cancer science, 2018)
In prostate cancer patients receiving second-line degarelix, local injection-site reactions were the most frequent adverse events. (Therapeutic advances in urology, 2015)
In the prostate cancer degarelix trial, one patient died of an unrelated cause. (Gan to kagaku ryoho. Cancer & chemotherapy, 2014)
In prostate cancer patients receiving degarelix, adverse-event incidence did not differ clinically between Korean and non-Asian trials. (Prostate international, 2015)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
240/80 mg monthly	Human	human	subcutaneous	12 months	Randomized trial in people · n = 283	Sun 2020
240 mg initial, then 80 mg monthly	Human	human	Not reported	12 weeks	Randomized trial in people · n = 244	Mason 2013
240 mg initially, then 480 mg every 84 days after day 28	Human	human	subcutaneous	day 28 to day 364	Randomized trial in people · n = 234	Ozono 2018
240/80 mg monthly	Human	human	Not reported	12 weeks	Randomized trial in people · n = 175	Axcrona 2012
240 mg once	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 96	Nickols 2022
2 injections of 120 mg degarelix acetate	Human	human	subcutaneous	2 weeks	Randomized trial in people · n = 52	Landgren 2020
240 mg on day 1 of cycle 1, then 80 mg on day 1 of cycles 2 through 6	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 51	Dellapasqua 2019
240/80 mg	Human	human	Not reported	3 months	Randomized trial in people · n = 40	Anderson 2013
240/80 mg	Human	human	subcutaneous	12 months	Randomized trial in people	Klotz 2008
240/160 mg	Human	human	subcutaneous	12 months	Randomized trial in people	Klotz 2008
240/80 mg	Human	human	Not reported	1 year	Randomized trial in people	Tombal 2010
240/80 mg once monthly	Human	human	Not reported	12 weeks	Randomized trial in people · n = 463	Mason 2017
240 mg initially, then 80 mg per month	Human	human	Not reported	4 months versus 10 months of monthly degarelix	Randomized trial in people · n = 90	Klotz 2018
2.8 mg single dose	Human	human	intravenous	Not reported	Randomized trial in people · n = 80	Olsson 2017
240 mg initial, then 80 or 160 mg monthly	Human	human	subcutaneous	12 months	Randomized trial in people	Klotz 2008
240 mg initial, then 80 mg monthly	Human	human	Not reported	12 months	Randomized trial in people	Damber 2012
240/80 or 240/160 mg monthly	Human	human	subcutaneous	12 months	Randomized trial in people	Iversen 2011
240 mg followed by 11 monthly doses of 80 mg	Human	human	Not reported	1 year	Trial in people without random groups · n = 25	Miller 2015
240/80 mg	Human	human	Not reported	median 27.5-month followup	Trial in people without random groups	Crawford 2011
80 or 160 mg maintenance; crossover starting dose 240 mg	Human	human	Not reported	up to 5 years	Trial in people without random groups	Crawford 2014
240 mg initial, 360 mg every 84 days	Human	human	subcutaneous	12 months	Trial in people without random groups	Ozono 2017
240 mg initial, 480 mg every 84 days	Human	human	subcutaneous	12 months	Trial in people without random groups	Ozono 2017
240 mg initial, then 80 or 160 mg monthly	Human	human	subcutaneous	12 months	Trial in people without random groups · n = 273	Ozono 2012
240 mg initial, then 80 or 160 mg monthly	Human	human	Not reported	3 months	Trial in people without random groups · n = 134	de 2011
200 mg starting dose	Human	human	Not reported	1 month	Trial in people without random groups · n = 127	Gittelman 2008
200 mg followed by 60 or 80 mg monthly	Human	human	Not reported	1 year	Trial in people without random groups · n = 127	Gittelman 2008
240/80 mg	Human	human	subcutaneous	12 months	Trial in people without random groups · n = 28	Ozono 2012
240/160 mg	Human	human	subcutaneous	12 months	Trial in people without random groups · n = 22	Ozono 2012
80 or 160 mg monthly	Human	human	Not reported	12 months	Trial in people without random groups · n = 13	Hoshi 2014
200 mg initial	Human	human	subcutaneous	3 days	Trial in people without random groups	Van 2008
240 mg initial	Human	human	subcutaneous	3 days	Trial in people without random groups	Van 2008
240 mg starting dose, then 80 mg every 28 days	Human	human	Not reported	7 months	Trial in people without random groups	You 2015
1-month doses of 20 to 240 mg or 3-month doses of 240 to 480 mg	Human	human	Not reported	average 22 months	Observational study · n = 1,704	Smith 2011
160 mg monthly maintenance	Human	human	subcutaneous	1 yr	Observational study	Van 2008
60 mg monthly maintenance	Human	human	Not reported	1 year	Observational study	Gittelman 2008
80 mg monthly maintenance	Human	human	Not reported	1 year	Observational study	Gittelman 2008
0.25-1.5 mg/kg	Animal	beagle dogs	subcutaneous or intramuscular	Not reported	Study in live animals · n = 27	Agersø 2003
0.3 to 10 microg/kg	Animal	rat	subcutaneous	Not reported	Study in live animals	Broqua 2002
12.5 microg/kg	Animal	rat	subcutaneous	Single injection	Study in live animals	Broqua 2002
50 microg/kg	Animal	rat	subcutaneous	Single injection	Study in live animals	Broqua 2002

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label reports prescription use. The regimen below is label information.

Reported routines and cautions

What people use it for

Maintenance treatment of advanced prostate cancer after the labeled loading doseS1

Reported regimens

Regimens that community sources report for Degarelix. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
FIRMAGON maintenance treatment for patients with advanced prostate cancer after the labeled starting dose. This regimen describes the US acetate formulation.Official label dosing of an approved product	subcutaneous injectionThe label restricts injection to the abdomen and administration to a healthcare professional. Injection sites must vary and avoid areas exposed to pressure.	80 mg per dose	every 28 days	Not stated	Single official US label source.	S1

Cautions

The label warns about hypersensitivity, QT prolongation, and fetal harm.S1

Status notes

Firmagon has EU authorisation for specified prostate cancer indications in adult men. The EU indications differ from the US label.S2

Community sources

S1Firmagon US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

This record covers one selected US label maintenance regimen. No separate non-vendor community regimen was assessed in this check. The full prescribing information controls preparation, administration, contraindications, and monitoring.

Questions and more

Ask a question about degarelix

The answer links to every study it uses.

What does the evidence say about degarelix?Is degarelix tested in people?Compare with Oxytocin Compare with Triptorelin (Trelstar, Decapeptyl)

Sources

Database: PepBank data for degarelix (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about degarelix

Degarelix

ApprovedNot banned in sport

Also known as Firmagon

What it is

Synthetic analog, 10 amino acids

Approval

Approved in the US and EU (Firmagon)

In sport

Not listed as banned by WADA

Studies

60 studies with results. All of them gave degarelix, with 329 results.
252 in people59 in animals18 in lab cells

Best study in people

Randomized controlled trial with 379 people (2025)

Clinical trials

148 registered: 39 active or planned, 55 with posted results

Community use

Maintenance treatment of advanced prostate cancer after the labeled loading dose

Dose as reported

Class

Species

Route

Duration

Design

Source

240/80 mg monthly

Human

human

subcutaneous

12 months

Randomized trial in people · n = 283

Sun 2020

240 mg initial, then 80 mg monthly

Human

human

Not reported

12 weeks

Randomized trial in people · n = 244

Mason 2013

240 mg initially, then 480 mg every 84 days after day 28

Human

human

subcutaneous

day 28 to day 364

Randomized trial in people · n = 234

Ozono 2018

240/80 mg monthly

Human

human

Not reported

12 weeks

Randomized trial in people · n = 175

Axcrona 2012

240 mg once

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 96

Nickols 2022

2 injections of 120 mg degarelix acetate

Human

human

subcutaneous

2 weeks

Randomized trial in people · n = 52

Landgren 2020

240 mg on day 1 of cycle 1, then 80 mg on day 1 of cycles 2 through 6

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 51

Dellapasqua 2019

240/80 mg

Human

human

Not reported

3 months

Randomized trial in people · n = 40

Anderson 2013

240/80 mg

Human

human

subcutaneous

12 months

Randomized trial in people

Klotz 2008

240/160 mg

Human

human

subcutaneous

12 months

Randomized trial in people

Klotz 2008

240/80 mg

Human

human

Not reported

1 year

Randomized trial in people

Tombal 2010

240/80 mg once monthly

Human

human

Not reported

12 weeks

Randomized trial in people · n = 463

Mason 2017

240 mg initially, then 80 mg per month

Human

human

Not reported

4 months versus 10 months of monthly degarelix

Randomized trial in people · n = 90

Klotz 2018

2.8 mg single dose

Human

human

intravenous

Not reported

Randomized trial in people · n = 80

Olsson 2017

240 mg initial, then 80 or 160 mg monthly

Human

human

subcutaneous

12 months

Randomized trial in people

Klotz 2008

240 mg initial, then 80 mg monthly

Human

human

Not reported

12 months

Randomized trial in people

Damber 2012

240/80 or 240/160 mg monthly

Human

human

subcutaneous

12 months

Randomized trial in people

Iversen 2011

240 mg followed by 11 monthly doses of 80 mg

Human

human

Not reported

1 year

Trial in people without random groups · n = 25

Miller 2015

240/80 mg

Human

human

Not reported

median 27.5-month followup

Trial in people without random groups

Crawford 2011

80 or 160 mg maintenance; crossover starting dose 240 mg

Human

human

Not reported

up to 5 years

Trial in people without random groups

Crawford 2014

240 mg initial, 360 mg every 84 days

Human

human

subcutaneous

12 months

Trial in people without random groups

Ozono 2017

240 mg initial, 480 mg every 84 days

Human

human

subcutaneous

12 months

Trial in people without random groups

Ozono 2017

240 mg initial, then 80 or 160 mg monthly

Human

human

subcutaneous

12 months

Trial in people without random groups · n = 273

Ozono 2012

240 mg initial, then 80 or 160 mg monthly

Human

human

Not reported

3 months

Trial in people without random groups · n = 134

de 2011

200 mg starting dose

Human

human

Not reported

1 month

Trial in people without random groups · n = 127

Gittelman 2008

200 mg followed by 60 or 80 mg monthly

Human

human

Not reported

1 year

Trial in people without random groups · n = 127

Gittelman 2008

240/80 mg

Human

human

subcutaneous

12 months

Trial in people without random groups · n = 28

Ozono 2012

240/160 mg

Human

human

subcutaneous

12 months

Trial in people without random groups · n = 22

Ozono 2012

80 or 160 mg monthly

Human

human

Not reported

12 months

Trial in people without random groups · n = 13

Hoshi 2014

200 mg initial

Human

human

subcutaneous

3 days

Trial in people without random groups

Van 2008

240 mg initial

Human

human

subcutaneous

3 days

Trial in people without random groups

Van 2008

240 mg starting dose, then 80 mg every 28 days

Human

human

Not reported

7 months

Trial in people without random groups

You 2015

1-month doses of 20 to 240 mg or 3-month doses of 240 to 480 mg

Human

human

Not reported

average 22 months

Observational study · n = 1,704

Smith 2011

160 mg monthly maintenance

Human

human

subcutaneous

1 yr

Observational study

Van 2008

60 mg monthly maintenance

Human

human

Not reported

1 year

Observational study

Gittelman 2008

80 mg monthly maintenance

Human

human

Not reported

1 year

Observational study

Gittelman 2008

0.25-1.5 mg/kg

Animal

beagle dogs

subcutaneous or intramuscular

Not reported

Study in live animals · n = 27

Agersø 2003

0.3 to 10 microg/kg

Animal

rat

subcutaneous

Not reported

Study in live animals

Broqua 2002

12.5 microg/kg

Animal

rat

subcutaneous

Single injection

Study in live animals

Broqua 2002

50 microg/kg

Animal

rat

subcutaneous

Single injection

Study in live animals

Broqua 2002

Context

Route

Amount

How often

How long

Agreement

Sources

FIRMAGON maintenance treatment for patients with advanced prostate cancer after the labeled starting dose. This regimen describes the US acetate formulation.Official label dosing of an approved product

subcutaneous injectionThe label restricts injection to the abdomen and administration to a healthcare professional. Injection sites must vary and avoid areas exposed to pressure.

80 mg per dose

every 28 days

Not stated

Single official US label source.

Degarelix

Degarelix at a glance

What is degarelix?

The history of degarelix

Degarelix structure and chemistry

What degarelix studies show

Sex hormones and fertility

Cancer

Sexual and women's health

Kidneys and bladder

Heart and blood vessels

Daily life and fitness

Key degarelix studies

Degarelix clinical trials

Is degarelix approved?

Degarelix side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about degarelix

Related peptides

Sources

Degarelix

Degarelix at a glance

What is degarelix?

The history of degarelix

Degarelix structure and chemistry

What degarelix studies show

Sex hormones and fertility

Cancer

Sexual and women's health

Kidneys and bladder

Heart and blood vessels

Daily life and fitness

Key degarelix studies

Degarelix clinical trials

Is degarelix approved?

Degarelix side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about degarelix

Related peptides

Sources